This Nature review provides an overview of the epidemiology, clinical presentation, and pathogenesis of visceral leishmaniasis, as well as diagnostics and control strategies.
The article, published in 2007, is available here.
I am the CEO of the Brazil-based research network Farmabrasilis and would like to present the immunomodulator P-MAPA, which has shown to be effective in vivo against intracellular pathogens -- latest papers focused on leishmaniasis and tuberculosis .
After reading your remarkable paper ( Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?) I want to draw your attention on the impressive results of the immunodulator P-MAPA, a drug in pipeline, on leishmaniasis.
I think that P-MAPA may be a drug candidate to be used in the treatment of Leishmaniasis combined with chemotherapy aiming the elimination of parasites by means of an initial treatment with chemotherapy, followed by modification of the patient’s immune response by the drug candidate.
If such combination works, the outcomes may include a quick recovery and control of remaining parasites leading to clearance of infection.
PubMed for P-MAPA :http://www.ncbi.nlm.nih.gov/pubmed/?term=P-MAPA